Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciencesFRA:82P +1.82%83 Return-on-Tangible-Asset is 1.37% as of Mar. 2026, which is 342% above its 10-year median of 0.31. GuruFocus rates FRA:82P with a GF Score™ of 83/100 and a GF Value™ of €26.03. The stock has 8 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Pacira BioSciences ranks worse than 61.71% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pacira BioSciences's annualizedNet Income for the quarter that ended in Mar. 2026 was €10.1 Mil. Pacira BioSciences's average total tangible assets for the quarter that ended in Mar. 2026 was €735.7 Mil. Therefore, Pacira BioSciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 1.37%.
The historical rank and industry rank for Pacira BioSciences's Return-on-Tangible-Asset or its related term are showing as below:
FRA:82P'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -10.82 Med: 0.31 Max: 17.06
Current: 0.53
During the past 13 years, Pacira BioSciences's highest Return-on-Tangible-Asset was 17.06%. The lowest was -10.82%. And the median was 0.31%.
FRA:82P's Return-on-Tangible-Asset is ranked worse than 61.71% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.155
vs FRA:82P: 0.53
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Pacira BioSciences Return-on-Tangible-Asset Related Terms
Pacira BioSciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, BIOA: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 1.37% mean?
Pacira BioSciences (FRA:82P) has a Return-on-Tangible-Asset of 1.37% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pacira BioSciences and its competitors. This is 342% above median its historical median of 0.31. According to the industry distribution chart, Pacira BioSciences ranks #622 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 61.7%.
Is Pacira BioSciences' Return-on-Tangible-Asset too high?
Pacira BioSciences' current Return-on-Tangible-Asset of 1.37% is 342% above median its 10-year median of 0.31. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Pacira BioSciences' value of 1.37% is 56.6% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #622 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Return-on-Tangible-Asset compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #622 out of 1008 companies for Return-on-Tangible-Asset. This places Pacira BioSciences in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Pacira BioSciences' value of 1.37% is 56.6% below this benchmark. While the company's 10-year median is 0.31 vs. the industry median of 3.16, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Return-on-Tangible-Asset of 1.37% is 56.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Return-on-Tangible-Asset is 1.37%, which is 342% above median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Return-on-Tangible-Asset of 1.37%. The stock's GF Value™ is €26.03, compared to a current price of €22.40 — trading 13.9% below its estimated fair value. The current Return-on-Tangible-Asset is 1.37%, which is 342% above median its 10-year median of 0.31 and 56.6% below the Drug Manufacturers industry median of 3.16. Pacira BioSciences' overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Return-on-Tangible-Asset is 1.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.40 is trading 13.9% below its estimated GF Value™ of €26.03.
Key valuation signals for FRA:82P:
Return-on-Tangible-Asset: 1.37% (342% above median its 10-year median of 0.31)
GF Value™: €26.03 vs. price of €22.40 (13.9% below fair value)
Industry Position: 56.6% below the Drug Manufacturers median (#622 of 1008)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
83GF Score
Get the complete analysis for FRA:82P
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
